

21 years later...one Group, two strategies Separation scheduled for Q4 2016

April 2016

The Galenica Group - Excellence in the healthcare market


Pharmacosmos, Exh. 1059, p. 1

Galenica Group Overview






Galenica Group Financial Profile




(*) like-for-like (excludes non-cash one off effects of CHF39m in 2013)

Galenica Group Stock market value from CHF 250M to >9BN




Pharmacosmos, Exh. 1059, p. 4

Galenica Group Leadership team organisation – Long-term sustainability




April 2016 - © Galenica Group

Galenica Group Corporate Timeline



Galenica Group Galenica vision for the separation: 2 listed companies in Q4 2016




April 2016 - © Galenica Group



Vifor Pharma "Vifor Pharma will become a successful, standalone global speciality pharma company"



Vifor Pharma Executive Committee



April 2016 - © Galenica Group




Vifor Pharma Excellent progress made in 2015

Solid Results	 Impressive top line growth (+36.9%) and EBIT growth (+25.7%), offsetting the planned decline of other revenue (CHF 92.6M)
Ferinject [®] / Injectafer [®]	 Strong growth in value of 33% (42% excluding FX impact) and in volume (+49%) Ferinject[®] is now available in 65 countries
Mircera®	 Exclusive license agreement with Roche for the commercialization of the long-acting ESA Mircera[®] in the U.S. Significant sales already generated in 2015 (CHF 206.8M)
Veltassa®	 Exclusive partnership with Relypsa to commercialize Veltassa[®] worldwide (except U.S./Japan) for the treatment of hyperkalemia EMA filing in Spring 2016



Vifor Pharma Summary of marketed products





Infectious diseases / OTX franchise (e.g. respiratory/urinary infections)



Infectious Disease / OTX⁽¹⁾

Diversified portfolio of prescribed non-prescription medicines

BRONCHO-VAXOM[®]

URO-VAXOM[®] Odicynone

(1) Select key products only.

April 2016 - © Galenica Group

Pharmacosmos, Exh. 1059, p. 11



Vifor Pharma Fully exploit potential of Ferinject[®]/Injectafer[®]



Ferinject [®] sales						
	FY 2014	FY 2015				
in MCHF	188.3	250.9				
±% prior year	+19.0%	+33.2%				

Ferinject [®] numbers of units (100mg) sold						
	FY 2014	FY 2015				
±% prior year	+28.0%	+49.0%				

Launched: 65 countries

Approved, not yet in the market: 7 countries

Expected approval in 2016: 5 countries

Vifor Pharma Ferinject[®] / Injectafer[®]

Patients treated: >3 million

First, high-dose, non-dextran IV iron

- Ferinject[®]: Single dose up to 1,000mg
- Injectafer® (branded name in the U.S.): Single dose up to 750mg
- Short administration time:
 - 200mg in fast push injection
 - 1,000mg / 750mg (U.S.) in 15-minute infusion/injection

Total repletion in few visits

Lower medical care costs

- Worldwide clinical trials have established a large base of clinical evidence
- Approved in 72 countries, launched in 65 countries
- FDA approval for the treatment of iron deficiency anaemia (25 July 2013)
- Licensed to Zeria Pharmaceutical in Japan. Phase 3 study started in 2016

Net sales 2015: CHF 250.9M (+33% PY)


GALENICA

Unit (100mg) Sold 2015: +49% PY





Vifor Pharma Injectafer[®] - Market leader in "high-dose" segment



Launch Progress

- Injectafer[®] high dose segment sales leader
- High dose segment represents 23.1% of total IV iron market volume
- Injectafer[®] value share December YTD of 47% (+19 pts vs. prior YTD) in High Dose segment
- Injectafer[®] driving high dose segment growth +19.4% versus prior YTD
- Injectafer[®] contributing 100% of the High Dose growth





Vifor Pharma Venofer[®] & Iron Sucrose Similars

- Positioning of Venofer[®] as drug of choice in HD with a distinct safety and efficacy profile compared to ISS preparations
- In addition to clinical data on differences in efficacy, new clinical observation reports increased adverse event rate of ISS
- Major authorities recognize the complexity of the product and discuss the limitation of the approval of ISS preparations through the generic pathway
- Venofer[®] has 85 marketing authorizations worldwide

April 2016 - © Galenica Group

ROTTEMBOURG STUDY DEMONSTRATES SUPERIORITY OF VENOFER® vs ISS

- Patients with anemia and iron deficiency treated successfully with erythropoiesis-stimulating agents (ESA) and Venofer[®] switched to FerMylan[®]
- Outcome to regain control of hemoglobin: + 35% IV iron, + 14% ESA, + 12% costs
- A recent study conducted in Spain confirmed the Rottembourg study: «The treatment with generic IV iron needs a higher dose of iron and ESA to keep hemoglobin stable»




15

Net sales 2015:

CHF 108.9M (-4% PY)



Vifor Pharma Global Market Leader in IV and Oral Iron



(1) World Health Organization (WHO) Micronutrient deficiencies: Iron deficiency anaemia. Available at http://www.who.int/nutrition/topics/ida/en/. Last accessed: 10 November 2014.


(2) Unicef http://www.unicef.org/nutrition/23964_iron.html Last accessed: 10 November 2014.

(3) Vos T Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet. 2012 Dec 15;380(9859):2163-96.

April 2016 - © Galenica Group




Vifor Pharma Health economic outcomes of Ferinject[®] vs other i.v. iron



Source: Szucs et al 2009, University of Zurich, ASH HE.




Vifor Pharma i.v. Iron Market - Large potential outside dialysis



- 70% of the worldwide i.v. market is in Nephrology (CKD 3-5) vs 9% in Switzerland

- 2015 Swiss Sales in i.v. iron amounted to CHF 53.7 million
- Still large potential in Switzerland in women's health (fatigue) & elderly people
- Focused therapeutic areas (TAs): Nephrology (ND-CKD), Gastroenterology, Cardiology

Vifor Pharma Swiss market: Venofer® and Ferinject® sales history




Source: IMS

Vifor Pharma Worldwide i.v. iron market


- Vifor Pharma owns 2/3 of the worldwide i.v. iron market with 66% market share (70% USA, 80% Europe)
- Venofer[®] remains the «gold» standard product in dialysis patients
- Ferinject[®] offers significant opportunities outside dialysis (higher dosing / faster infusion time)

World i.v. iron market (sales)

in million CHF



World i.v. iron market share (value)





Source: IMS


Vifor Pharma European i.v. iron market

- The European market represents 27% of the worldwide i.v. iron market
- Vifor Pharma has increased its market share to +80% in a doubled market since 2008
- Market growth driven by Ferinject[®] (mostly outside dialysis)

European i.v. iron market (sales)







Source IMS


in million CHF

Pharmacosmos, Exh. 1059, p. 21

GALENICA


Vifor Pharma North american i.v. iron market

- The North American market represents >50% of the worldwide i.v. iron market
- Venofer[®] leads the USA iron market with 50% market share
- The USA market is mostly a «nephrology» market, leaving significant opportunities for Injectafer[®] in other therapeutic areas (TAs)




USA i.v. iron market (sales)

USA i.v. iron market share (value)





Vifor Pharma Main clinical studies for key brands





- Paediatric trial to fulfill our regulatory commitment
- Two non-interventional studies to assess adherence

GALENICA

Vifor Pharma Infectious Disease/OTX

BRONCHO-VAXOM®

- Respiratory immuno enhancer
- #1 Broncho-Vaxom[®] marketed in 65 countries

- Urinary immuno enhancer
- Marketed in 56 countries worldwide

DOXIUM°

- Micro-vascular complications
- Doxium[®] presence in 47 countries worldwide

dicynone[®]

- Antihemorragic
- Worldwide presence in 42 countries




Net sales 2015: CHF 122M








Vifor Fresenius Medical Care Renal Pharma Structure, scope & objectives



- Exclusive agreement for the commercialization of Roche's drug Mircera[®] in the US and Puerto Rico.
- Partnership agreement with Relypsa for the commercialization of Veltassa[®] worldwide (except USA/Japan) for the treatment of hyperkalaemia.



Most importantly, patients benefit most from faster access to high-quality care

(1) Velphoro IP rights owned by Vifor FMC Renal Pharma. 25

Vifor Fresenius Medical Care Renal Pharma

From Strong Brands to Therapeutic Area Portfolios





Vifor Fresenius Medical Care Renal Pharma Velphoro[®] - Oral Iron Phosphate Binder

- Velphoro[®] is a novel iron-based (non-calcium) phosphate binder with good phosphate binding capacity
- Velphoro[®] is is a calcium-free iron-based phosphate binder offering safety, efficacy, simplicity and high acceptance with low pill burden (3 pills per day)
- Pivotal phase III study (> 1,000 patients) met primary and secondary endpoints, with fewer pills than sevelamer carbonate (3.3 pills per day after 52 weeks)
- Strong commercial partners with Fresenius Medical Care in U.S. and Europe
- U.S: Approved by FDA (27 November 2013) and launched in March 2014
- EU: Approved by EMA (26 August 2014) and first launch in Germany in October 2014, launch in U.K. on 04 January 2015
- Japan: Launch of P-TOL[®] by the local partner (Kissei) on 27 November 2015
- Velphoro[®] is approved in 37 countries, launched in 17 countries

April 2016 – © Galenica Group





Pharmacosmos, Exh. 1059, p. 27

- Mircera[®]: A long-acting* erythropoiesis-stimulating agent (ESA)
- Long-acting ESAs expected to reach significant market shares
- Used by Fresenius Medical Care in the USA since December 2014 (pilot phase)
- Excellent feedback from physicians and clinic staff
- Provides opportunities to strengthen our existing partnerships aiming at leadership in anemia treatment in ND-CKD and dialysis
- * for bi-weekly or monthly treatment



Pharmacosmos, Exh. 1059, p. 28



Vifor Fresenius Medical Care Renal Pharma Veltassa[™]

- Veltassa[™] addresses a large unmet medical need elevated potassium levels are leading to increased mortality
- Veltassa[™] is the first hyperkalemia drug with tolerability and efficacy profile enabling chronic daily administration
- Exclusive license to commercialize Veltassa® outside the U.S. and Japan
- VFMCRP intends to file with EMA in Spring 2016
- Veltassa[™] approved by FDA on 21 October 2015
- Great opportunity for VFMCRP to expanding nephrology portfolio and jointly with Vifor to leverage opportunities in cardio-renal
- Highly effective and well tolerated




29

April 2016 – © Galenica Group

Renal Pharma

Vifor Pharma **Global Network & Footprint**





Galenica Santé




"Galenica Santé aims to be the first choice in Switzerland for health, beauty and well-being!"

April 2016 - © Galenica Group



Galenica Santé Organisation and management structure



April 2016 - © Galenica Group


Pharmacosmos, Exh. 1059, p. 32

Galenica Santé Highlights 2015


Galenica Santé	 Solid top line growth (+3.9%) and EBIT growth (+21.7%), supported by Vifor Consumer Health transferred to Galenica Santé as of 01 July 2015 (+14.4% EBIT growth on a comparable basis) New organisation and management structure since September 2015
Products & Brands	 OTC products in Switzerland clearly outperformed the market Successful transfer of Vifor Consumer Health to Galenica Santé Galenica Santé established overarching product and category teams
Retail	 Significant improvement in profitability Unified management of Amavita & Sun Store
Services	 Niederbipp expansion on track Further improvement in profitability



Galenica Santé The vision for Galenica Santé



Galenica Santé Health & Beauty segment - Number 1 in Switzerland



Own	Ама√іта ╋	PHARMACIE	vitality		Others
318		102	64 ⁽³⁾	1	6


- Network of 318 own pharmacies and 173 independent partners
- Approx. 100,000 customers daily
- Network: No. 1 with 491 pharmacies in the best locations
- MediService: No. 1 as Specialty Pharmacy
- Objective of **500 pharmacies**
- #3 player in Swiss OTC market
- Preferred OTC partners for Swiss pharmacists
- Largest OTC sales force in Switzerland
- Over 60 brands with focus areas: Pain & Cough-Cold-Respiratory
- exclusively in pharmacies and drugstores
- G-Pharma: 180 references for own brands from our pharmacies and from Galexis

^{1.)} Source: PharmaSuisse – Annual report 2014

^{2.) 318} own pharmacies (Amavita and Sun Store) and 178 independent partners (under Winconcept partnerships).

^{3.)} Galenica holds 49% of Coop Vitality. Consolidated at equity.

Galenica Santé **Retail - Challenges and focus**



GALENICA

Pharmacosmos, Exh. 1059, p. 36

April 2016 - © Galenica Group

Galenica Santé Products & Brands – A strong OTC partner in Switzerland

Triofan

Triofan®

A full range of consumer health products... —

Algifor®

...and leading brands in Switzerland

Algifor -







Net sa	les 2015
CHF	113M

GALENICA



Sanadermil®



Ginsana®

April 2016 - © Galenica Group



Formoline®



ANT

Anti-Brumm[®]

Dermaplast®




Oral-B[®]



Clearblue[®]




Galenica Santé Services - Positioning in markets





Galenica Santé Services - Wholesale & pre-wholesale







April 2016 - © Galenica Group


Galenica Group Key Financials

in million CHF	2014	2015	Δ %
Net Sales – Vifor Pharma	706.2	967.0	+36.9%
Net Sales – Galenica Santé	2,781.9	2,891.3	+3.9%
Consolidation Group	-71.8	-66.8	
Net Sales – Galenica Group	3,416.2	3,791.6	+11.0%
Other operating income	254.7	137.5	-39.7%
Operating revenue	3,671.0	3,945.2	+7.5%
COGS	-2,185.4	-2,333.6	+6.8%
OPEX	-1,038.7	-1,074.2	+3.4%
EBITDA	446.8	537.4	+20.3%
EBIT	370.2	450.8	+21.8%
ROS (%)	10.8%	11.9%	
Net profit (before minorities)	312.0	370.0	+18.6%
Non-controlling interests	-27.5	-68.9	+150.4%
Net profit (after minorities)	284.5	301.1	+5.8%
EPS (in CHF)	43.9	46.5	



Galenica Group Free cash flow & investments

In million CHF	Actual 2013	Actual 2014	Actual 2015
Cash flow from operating activities	329.0	355.8	522.2
+ Proceeds from property, plant and equipment, investment properties, intangible assets, financial assets and securities	12.7	12.9	52.2
- Investments in property, plant and equipment, investment properties and intangible assets	(71.6)	(69.9)	(164.9)
- Investments in financial assets, associates & subsidiaries	(49.4)	(102.0)	(49.4)
Free cash flow	220.7	196.9	360.1




Investment intangible assets

Investment tangible assets

April 2016 - © Galenica Group

Galenica Group Balance sheet – key figures

in million CHF / %	Actual 2013	Actual 2014	Actual 2015
Interest coverage	14.9	17.1	26.4
Debt coverage	0.94	0.76	0.30
Gearing	28.1%	19.5%	8.1%
Operating net working capital ¹⁾	521	536	563



% of Total liabilities and shareholders' equity


April 2016 - © Galenica Group

GALENICA

Pharmacosmos, Exh. 1059, p. 43

GALENICA


Galenica Group Key financials - EBIT in 2015: +21.8%



April 2016 – © Galenica Group

Pharmacosmos, Exh. 1059, p. 44


Vifor Pharma Net sales in 2015: +36.9%



GALENICA




Galenica Santé Substantial EBIT/ROS progress






Health & Beauty



April 2016 - © Galenica Group

Services





Galenica Group Contact information

Jörg Kneubühler
 CEO Galenica Santé & CFO Galenica Group
 Tel.: +41 58 852 81 11
 Mail: kneubuehler@galenica.com

- Søren Tulstrup

CEO Vifor Pharma Tel.: +41 58 851 80 87 Mail: <u>soren.tulstrup@viforpharma.com</u>

Investor Relations: Julien Vignot

Head Investor Relations Tel.: +41 58 852 85 29 Mail: <u>investors@galenica.com</u>

<u>Media</u>:

Christina Hertig

Head Corporate Communication Tel.: +41 58 852 85 17 Mail: <u>media@galenica.com</u>



Disclaimer

Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this presentation as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its of their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forwardlooking statements contained in this presentation or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation.